From JACC: Mortality Benefit of Rivaroxaban Plus Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease
Deepak Bhatt, MD, FACC
Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital, Professor of Medicine, Harvard Medical School, Boston, MA
Interviewer: Spencer B. King III, MD, MACC
Professor of Medicine Emeritus, Emory University School of Medicine, Atlanta, GA
Correspondent: Arjun Majithia, MD
Interventional Cardiology, Lahey Hospital and Medical Center, Burlington, MA
The combination of rivaroxaban (2.5 mg twice daily) and aspirin (100 mg/day) reduces major adverse cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease, compared with aspirin (100 mg/day) alone.